Nicotine withdrawal symptoms

Nicotine Delivery Systems. For all transdermal nicotine products, the hypothesis is that continuous deflvery of nicotine [34-11-3] ne t trough levels during smoking should alleviate physical nicotine withdrawal symptoms and allow the smoker to concentrate on eliminating the behavioral aspects of addiction. 

Since nicotine has wide ranging effects on the central nervous system it seems likely that pharmacogenomic effects on the development of nicotine dependence will span several neurotransmitter systems. One study found an association between a polymorphism in dopamine /1-hydroxylase and level of tobacco consumption [20]. This enzyme is important in noradrenaline synthesis and it is tempting to speculate that genetically regulated variations in activity might influence susceptibility to nicotine withdrawal symptoms mediated by noradrenergic pathways, but more information is required on the molecular effects of the polymorphism. 

Similarly opioid peptides are important in nicotine addiction and may have a role in causing nicotine withdrawal symptoms in some smokers [35]. Opioid antagonists such as naltrexone are licensed treatments for dependence syndromes arising from other addictive drugs and could also be of use in some smokers to aid nicotine withdrawal [59] although there is no definitive evidence overall that they are beneficial [60]. 

As an aid to smoking cessation for the relief of nicotine withdrawal symptoms. Use as part of a comprehensive behavioral smoking-cessation program. 

Mechanism of Action An aminoketone that blocks the reuptake of dopamine and norepinephrine at CNS presynaptic membranes, increasing their availability at postsynaptic receptor sites. Therapeutic Effect Relieves depression and nicotine withdrawal symptoms. 

Transdermal nicotine is nsed in the relief of nicotine withdrawal symptoms in patients attempting smoking cessation. Two natnral alkaloids, nicotine and lobeline, exhibit peripheral actions by stimnlating antonomic ganglia. Nicotine was hrst isolated from leaves of tobacco, Nicotiana tabacum. Nicotine is of considerable medical signihcance becanse of its toxicity, presence in tobacco, and propensity for conferring a dependence on its nsers. 

Bupropion appears to reduce nicotine withdrawal symptoms and may simulate the actions of nicotine on the brain reward system. The most common side-effects related to bupropion are insomnia (30-45% at a dose of 300 mg/day) and dry mouth. Other commonly reported adverse events include hypertension, headache, and nausea. Seizures are a known risk associated with the use of somewhat higher doses compared with other antidepressants (0.1-0.4%), especially for the immediate-release form of the drug and when given at dosages of 450 mg/day or higher. Bupropion, unlike the TCAs, is virtually free of adverse cardiovascular effects, which makes it quite attractive for specific populations. 

Using a nicotine patch or chewing nicotine gum is the most successful way to help with the nicotine withdrawal symptoms. 

The lOM report describes the effect of THC, the primary psychoactive ingredient in marijuana cannabinoids, which are the compounds related to THC and marijuana, the unpurified plant substances. The lOM report studied the effects of isolated cannabioids and concluded that they have a natural role in pain modulation, control of movement, and memory. The role on cannabioids in the immune system was unclear and the report concluded that the brain develops tolerance to cannabioids. While animal research demonstrated dependence on cannabioids, the potential for dependence was seen as occurring under a more narrow range of conditions than for drugs such as minor tranquilizers, opiates, cocaine, or nicotine. Withdrawal symptoms were observed in animal studies but were mild compared to drugs such as minor tranquiflzers or opiates. 

---